Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 12, 2011, Pages 3809-3812

  Kim, Heung Jae ^a   Kwak, Woo Young ^a   Min, Jong Pil ^a   Lee, Jae Young ^a   Yoon, Tae Hyun ^a   Kim, Ha Dong ^a   Shin, Chang Yell ^a   Kim, Mi Kyung ^a   Choi, Song Hyen ^a   Kim, Hae Sun ^a   Yang, Eun Kyoung ^a   Cheong, Ye Hwang ^a   Chae, Yu Na ^a   Park, Kyung Jin ^a   Jang, Ji Myun ^a   Choi, Soo Jung ^a   Son, Moon Ho ^a   Kim, Soon Hoe ^a   Yoo, Moohi ^a   Lee, Bong Jin ^b  

^a Dong A Pharmaceutical Company   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

DA 1229; Dipeptidyl peptidase IV; DPP 4; DPP 4 inhibitor; DPP IV; GLP 1

Indexed keywords

4 [3 AMINO 4 (2,4,5 TRIFLUOROPHENYL)BUTANOYL] 3 (TERT BUTOXYMETHYL)PIPERAZIN 2 ONE; ANTIDIABETIC AGENT; DA 1229; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IC 50; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; HUMANS; INHIBITORY CONCENTRATION 50; PIPERAZINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 79957865337     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.04.029     Document Type: Article

References (22)

1. Nathan, D. M.; Buse, J. B.; Davidson, M. B.; Ferrannini, E.; Holman, R. R.; Sherwin, R.; Zinman, B. Diabetes Care 2009, 32, 193.
2. DeFronzo, R. A. Diabetes 2009, 58, 773.
3. Knudsen, L. B. J. Med. Chem. 2004, 47, 4128.
4. Murphy, K. G.; Dhillo, W. S.; Bloom, S. R. Endocr. Rev. 2006, 27, 719.
5. For recent reviews, see: (a) Mest, H.-J.; Mentlein, R. Diabetologia 2005, 48, 616;
6. (b) Weber, A. E. J. Med. Chem. 2004, 47, 4135;
7. (c) Drucker, D. J. Expert Opin. Invest. Drugs 2003, 12, 87;
8. (d) Augustyns, K.; Van der Veken, P.; Senten, K.; Haemers, A. Expert Opin. Ther. Patents 2003, 13, 499.
9. Villhauer, E. B.; Coppola, G. M.; Hughes, T. E. Annu. Rep. Med. Chem. 2001, 36, 191.
10. Drucker, D. J.; Nauck, M. A. Lancet 2006, 368, 1696.
11. Ahren, B. Expert Opin. Emerg. Drugs 2008, 13, 593.
12. Pei, Z. Curr. Opin. Drug Disc. Dev. 2008, 11, 512.
13. Gwaltney, S. L., II Curr. Top. Med. Chem. 2008, 8, 1545.
14. Xu, J. et al Bioorg. Med. Chem. Lett. 2004, 14, 4763.
15. Brockunier, L. L. et al Bioorg. Med. Chem. Lett. 2004, 14, 4759.
16. Oefner, C.; D'Arcy, A.; Sweeney, A. M. Acta Crystallogr., Sect. D 2003, 59, 1206.
17. Kim, D.; Wang, L.; Beconi, M. J. Med. Chem. 2005, 48, 141.
18. DPP-4 inhibition assay: Inhibitors at various concentrations were incubated with 20 ng/ml rhDPP-4 enzyme and 50 μMH-Gly-Pro-AMC for 1 h at 25 °C. The fluorescence (360 nm excitation/465 nm emission) was measured after 1 h.
19. Aertgeerts, K.; Ye, S.; Tennant, M. G. Protein Sci. 2004, 13, 412.
20. Compound 5f or vehicle (0.5% methylcellulose) was treated orally and then challenged with glucose (2 g/kg) 30 min post-dose. The blood glucose excursion profile from 0 to 120 min was used to integrate an area under for curve (AUC) and percent inhibition values for each treatment were generated from the AUC data normalized to the non-glucose controls.
21. Off target selectivity was screened by MDS pharm service pharmacology packages: LeadProfilingScreen®, EnzymeProfilingScreen®.
22. Kim, H. J.; Kim, H. D.; Kwak, W. Y. Diabetes 2008, 57. 2611-PO.